Join
Live feed
·
NEWSReleasevia Quantisnow
Merck & Company Inc. logo
Moderna Inc. logo

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
MRK· Merck & Company Inc.MRNA· Moderna Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRK (Merck & Company Inc.), MRNA (Moderna Inc.) and more on Quantisnow.